RAPT Therapeutics, Inc. (RAPT) DCF Valuation

RAPT Therapeutics, Inc. (RAPT) DCF Valuation
  • ✓ Completamente Editable: Adáptelo A Sus Necesidades En Excel O Sheets
  • ✓ Diseño Profesional: Plantillas Confiables Y Estándares De La Industria
  • ✓ Predeterminadas Para Un Uso Rápido Y Eficiente
  • ✓ No Se Necesita Experiencia; Fáciles De Seguir

RAPT Therapeutics, Inc. (RAPT) Bundle

DCF model
Get Full Bundle:
$25 $15
$12 $7
$12 $7
$12 $7
$12 $7
$12 $7
$12 $7
$12 $7
$12 $7

TOTAL:

Engineered for accuracy, our RAPT (RAPT) DCF Calculator empowers you to evaluate RAPT Therapeutics, Inc. valuation using current financial data, offering complete flexibility to modify all essential parameters for enhanced projections.


Discounted Cash Flow (DCF) - (USD MM)

Year AY1
2019		 AY2
2020		 AY3
2021		 AY4
2022		 AY5
2023		 FY1
2024		 FY2
2025		 FY3
2026		 FY4
2027		 FY5
2028
Revenue .0 5.0 3.8 1.5 .0 .0 .0 .0 .0 .0
Revenue Growth, % 0 0 -24.38 -59.95 -100 -46.08 -46.08 -46.08 -46.08 -46.08
EBITDA -42.3 -52.1 -68.2 -84.7 -125.8 .0 .0 .0 .0 .0
EBITDA, % 100 -1033.14 -1788.96 -5549.97 100 -20 -20 -20 -20 -20
Depreciation 1.3 1.1 1.0 2.8 1.2 .0 .0 .0 .0 .0
Depreciation, % 100 22.27 26.12 183.82 100 69.68 69.68 69.68 69.68 69.68
EBIT -43.6 -53.2 -69.2 -87.6 -127.1 .0 .0 .0 .0 .0
EBIT, % 100 -1055.41 -1815.08 -5733.79 100 -20 -20 -20 -20 -20
Total Cash 77.4 111.5 189.7 249.1 158.9 .0 .0 .0 .0 .0
Total Cash, percent .0 .0 .0 .0 .0 .0 .0 .0 .0 .0
Account Receivables .0 .0 .0 .0 .0
Account Receivables, % 100 0 0 0 100
Inventories .0 .0 .0 .0 .0 .0 .0 .0 .0 .0
Inventories, % 100 0 0 0 100 40 40 40 40 40
Accounts Payable 1.1 2.4 2.0 3.4 5.2 .0 .0 .0 .0 .0
Accounts Payable, % 100 47.26 52.43 220.37 100 79.94 79.94 79.94 79.94 79.94
Capital Expenditure -.9 -.4 -.8 -.8 -1.1 .0 .0 .0 .0 .0
Capital Expenditure, % 100 -7.89 -19.8 -55.34 100 -16.61 -16.61 -16.61 -16.61 -16.61
Tax Rate, % 0 0 0 0 0 0 0 0 0 0
EBITAT -44.3 -54.2 -68.2 -85.5 -127.1 .0 .0 .0 .0 .0
Depreciation
Changes in Account Receivables
Changes in Inventories
Changes in Accounts Payable
Capital Expenditure
UFCF -42.7 -52.3 -68.4 -82.2 -125.2 -5.2 .0 .0 .0 .0
WACC, % 5.83 5.83 5.83 5.82 5.83 5.83 5.83 5.83 5.83 5.83
PV UFCF
SUM PV UFCF -4.9
Long Term Growth Rate, % 2.00
Free cash flow (T + 1) 0
Terminal Value 0
Present Terminal Value 0
Enterprise Value -5
Net Debt -41
Equity Value 36
Diluted Shares Outstanding, MM 38
Equity Value Per Share 0.93

What You Will Get

  • Real RAPT Data: Preloaded financials – from revenue to EBIT – based on actual and projected figures for RAPT Therapeutics, Inc. (RAPT).
  • Full Customization: Adjust all critical parameters (yellow cells) such as WACC, growth %, and tax rates to fit your analysis.
  • Instant Valuation Updates: Automatic recalculations to assess the impact of changes on RAPT’s fair value.
  • Versatile Excel Template: Designed for quick edits, scenario testing, and comprehensive projections specific to RAPT Therapeutics, Inc. (RAPT).
  • Time-Saving and Accurate: Avoid the hassle of building models from scratch while ensuring precision and flexibility in your analysis.

Key Features

  • Comprehensive DCF Model: Offers in-depth unlevered and levered DCF valuation frameworks.
  • WACC Tool: Pre-configured Weighted Average Cost of Capital sheet with adjustable parameters.
  • Customizable Forecast Inputs: Adjust growth projections, capital expenditures, and discount rates.
  • Integrated Financial Ratios: Evaluate profitability, leverage, and efficiency ratios for RAPT Therapeutics, Inc. (RAPT).
  • Visual Dashboard and Charts: Graphical representations highlight essential valuation metrics for streamlined analysis.

How It Works

  • 1. Access the Model: Download and open the Excel file featuring RAPT Therapeutics, Inc.'s (RAPT) financial data.
  • 2. Modify Assumptions: Adjust key parameters such as growth projections, discount rates, and investment costs.
  • 3. Analyze Results Immediately: The DCF model automatically computes intrinsic value and net present value (NPV).
  • 4. Explore Scenarios: Evaluate various forecasts to assess different valuation possibilities.
  • 5. Present with Assurance: Deliver expert valuation analyses to aid your strategic decisions.

Why Choose This Calculator for RAPT Therapeutics, Inc. (RAPT)?

  • User-Friendly Interface: Perfect for both novice users and seasoned professionals.
  • Customizable Inputs: Effortlessly adjust parameters to suit your specific analysis needs.
  • Real-Time Feedback: Instantly observe changes in RAPT’s valuation as you modify inputs.
  • Preloaded Data: Comes with RAPT’s latest financial information for immediate evaluation.
  • Relied Upon by Experts: Favored by investors and analysts for making well-informed choices.

Who Should Use This Product?

  • Individual Investors: Make informed decisions about buying or selling RAPT Therapeutics, Inc. (RAPT) stock.
  • Financial Analysts: Streamline valuation processes with ready-to-use financial models specific to RAPT Therapeutics, Inc. (RAPT).
  • Consultants: Deliver professional valuation insights on RAPT Therapeutics, Inc. (RAPT) to clients quickly and accurately.
  • Business Owners: Understand how biotech companies like RAPT Therapeutics, Inc. (RAPT) are valued to guide your own strategy.
  • Finance Students: Learn valuation techniques using real-world data and scenarios related to RAPT Therapeutics, Inc. (RAPT).

What the Template Contains

  • Pre-Filled Data: Contains RAPT Therapeutics, Inc.'s historical financials and projections.
  • Discounted Cash Flow Model: An editable DCF valuation model with automated calculations.
  • Weighted Average Cost of Capital (WACC): A specific sheet for calculating WACC based on user-defined inputs.
  • Key Financial Ratios: Evaluate RAPT's profitability, operational efficiency, and financial leverage.
  • Customizable Inputs: Easily modify revenue growth rates, profit margins, and tax assumptions.
  • Clear Dashboard: Visuals and tables that summarize essential valuation outcomes.

No products were found matching.